Skip to content

   Pharma Publications

Neuropsychopharmacology
  • Prevention of late-life depression: a framework and prospectus for research
    Published on 2026-02-09
    7 months ago
  • Hair cortisol concentrations as a putative biomarker for suicidal behavior
    Published on 2026-02-05
    7 months ago
  • Effects of electroconvulsive shock on the function, circuitry, and transcriptome of dentate gyrus granule neurons
    Published on 2026-02-03
    7 months ago
  • Hypocretin receptor 1 blockade early in abstinence prevents incubation of cocaine seeking and normalizes dopamine transmission
    Published on 2026-02-03
    7 months ago
  • Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [11C]UCB-J positron emission tomography study
    Published on 2026-02-02
    7 months ago
  • Stereoselective, sex-dependent 5-HT2A receptor modulation of cortical plasticity by MDMA in mice
    Published on 2026-02-01
    7 months ago
  • Medial prefrontal-thalamic white matter microstructure is associated with harm avoidance in OCD: a discovery and transdiagnostic replication study
    Published on 2026-01-30
    8 months ago
« Previous 1 … 29 30 31 32 33 … 143 Next »
Journal of Psychopharmacology
  • β-blockers and risk of neuropsychiatric adverse events: An active-comparator restricted disproportionality on the FAERS
    Published on 2025-07-24
    1 year ago
  • Adverse event monitoring, assessment, and reporting in nutraceutical and phytoceutical trials for pediatric neuropsychiatric conditions: A systematic review
    Published on 2025-07-13
    1 year ago
  • A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction
    Published on 2025-07-11
    1 year ago
  • Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics
    Published on 2025-07-11
    1 year ago
  • The effect of betahistine on weight-related and metabolic measures in patients with schizophrenia treated with olanzapine and risperidone
    Published on 2025-07-08
    1 year ago
  • Evaluating the impact of cannabis oil for autistic children with and without concomitant medications: Insights from an open-label study
    Published on 2025-07-04
    1 year ago
  • Roles of the 5-HT1A receptor in zebrafish responses to potential threat and in sociality
    Published on 2025-07-01
    1 year ago
« Previous 1 … 29 30 31 32 33 … 154 Next »
European Neuropsychopharmacology
  • Predicting 10-year risk of chronic kidney disease in lithium-treated patients with bipolar disorder: A risk model development and internal cross-validation study
    Published on 2025-04-11
    1 year ago
  • Negative Symptoms in Schizophrenia: The Placebo Effect as a Barrier to Drug Development?
    Published on 2025-04-11
    1 year ago
  • Racial and ethnic diversity in zuranolone and brexanolone clinical trials for postpartum depression: A cross-sectional analysis of ClinicalTrials.gov
    Published on 2025-04-11
    1 year ago
  • Creatine as a treatment for depression: A brain bioenergetics perspective
    Published on 2025-04-11
    1 year ago
  • Frequency, correlates and outcomes of Benzodiazepine use during Cariprazine treatment: A pooled post-hoc analysis from four 6-week, placebo-controlled trials in patients with an acute exacerbation of schizophrenia
    Published on 2025-03-16
    1 year ago
  • Letter to the editor: Premature conclusions on antipsychotic continuation in environmentally conscious psychopharmacotherapy
    Published on 2025-03-13
    2 years ago
  • COSMIN systematic review and meta-analysis of the measurement properties of the PANSS-6
    Published on 2025-03-10
    2 years ago
« Previous 1 … 29 30 31 32 33 … 170 Next »

   Pharma Pub